Search
for
Sort by
Research 301–330 of 1000+
- Machine Learning--Enhanced Pharmacovigilance Assessment of Cardiac Adverse Events Associated With Minoxidil
- Impact of Reporter Type on Signal Detection of Cancer Therapy–Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
- Semaglutide and the Skin: An Overview of Current Evidence
- Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment
- Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system
- Characterization and Management of Adverse Events of Low-Dose Oral Minoxidil Treatment for Alopecia: A Narrative Review
- Cyclosporine-induced alopecia:a case report, FDA adverse event reporting system analysis and literature assessment
- Sun behaviors and quality of life after first cutaneous melanoma diagnosis
- Sun protection policies and behaviors among U.S. child care centers
- Circulating Androgen Concentrations and Risk of Incident Heart Failure in Older Men: The Cardiovascular Health Study
- Systemic treatments for alopecia areata: A systematic review
- Head and Neck Melanoma Incidence Trends in the Pediatric, Adolescent, and Young Adult Population of the United States and Canada, 1995-2014
- Chemotherapy-Induced Alopecia in Ovarian Cancer: Incidence, Mechanisms, and Impact Across Treatment Regimens
- Mining and analysis of adverse event signals of isotretinoin based on the real-world data of FAERS database
- A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
- Are finasteride-related penile curvature/Peyronie’s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases
- Pattern of short-term adverse effects in patients undergoing low-dose radioactive iodine therapy
- The Chemotherapy Use and Adverse Effects of Patients with Lung Cancer at Regional General Hospital in Surabaya, Indonesia
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review
- Environmental factors influencing hormone receptor positive breast cancer incidence: integrating chemical signatures from dust wipes with self-reported sources of exposure
- Association of Frailty Index with Clinical BPH Progression and Serious Adverse Events: the MTOPS Trial
- Supplementary Material for: GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-analysis of Incidence, Risk, Subtypes, and Mechanisms
- Supplementary Material for: GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-analysis of Incidence, Risk, Subtypes, and Mechanisms
- Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system
- Sexual, physical, and overall adverse effects in patients treated with 5α-reductase inhibitors: a systematic review and meta-analysis
- Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database
- Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study
- Retrospective Evaluation of the Impact of the COVID-19 Pandemic on the Incidence of Alopecia Areata in a Single Dermatological Department
- Chemotherapy-Induced Alopecia in Breast Cancer Patients: Treatment-Specific Incidence and Risk of Persistent Hair Loss